Wittycell S.A.S. is a spin off from the Institut Jean Godinot funded in Q3 2005. Wittycell S.A.S. is a biotechnology company using its proprietary technology to develop therapeutic and prophylactic vaccine adjuvants in the fields of oncology and infectious disease.

Wittycell S.A.S. is a biotechnology company focused on the development of innovative adjuvants that activate the immune system to better fight against infectious disease and cancer.

Wittycell is currently in pre-clinical development with two types of products, using its two technology platforms: 

• Lipid adjuvant products for therapeutic and prophylactic vaccines against infectious disease and cancer.
  
• Cellular adjuvant products for therapeutic vaccines against cancer. 

The combination of new techniques and manufacturing technologies is creating a new vaccine business, with new target diseases, larger markets, increasing demand and higher prices. Wittycell adjuvants have the potential to improve established vaccines and to allow the development of new vaccines for diseases that previously would not have been considered as vaccine targets.” The potential market encompasses over 90% of the total new vaccine market which represents over $18 bn market potential. 

Wittycell S.A.S has a strong intellectual property position with major partnerships including the Jean Godinot Institute, the Scripps Research Institute, the University of Chicago and the Brigham Young University.